NEWSWIRETODAY Press Release& Newswire Distribution | HOME
MOST TRUSTED NEWSWIRE PRESS RELEASE DISTRIBUTION
PRTODAY / NewswireToday press release distribution service network
Written by / Agency / Source: NeonDrum Ltd
Check Ads Availability|e-mail Article

Are you the owner of this article?, Turn it PREMIUM with your LOGO instead - and make it 3rd party Ads-Free! within the next hour!

Toumaz in Clinical Trial of Sensium-Enabled™ Digital Plaster - “Digital Plaster” Wireless Vital signs monitor now being trialed in patient settings in milestone imperial College London study (AIM: TMZ.L)
Toumaz in Clinical Trial of Sensium-Enabled™ Digital Plaster

 

NewswireToday - /newswire/ - Abingdon, United Kingdom, 2009/11/02 - “Digital Plaster” Wireless Vital signs monitor now being trialed in patient settings in milestone imperial College London study (AIM: TMZ.L).

   
 
Your Banner Ad Here instead - Showing along with ALL Articles covering Medical Services / Equipment Announcements

Replace these Affiliate Programs at ANYTIME! Your banner here within the next hour. Learn How!


 

Toumaz Technology Limited, the leading provider of ultra-low power wireless infrastructure for body monitoring solutions and wholly owned subsidiary of Toumaz Holdings (AIM: TMZ.L), today announces that it has begun clinical trials of its Sensium™ “digital plaster” wireless body monitor. The trial of the ultra-low power, ultra-small size body monitoring system is being conducted by a specialist clinical research team at Imperial College London. The study, which is being funded by global healthcare corporation CareFusion (a recent spin-out of Cardinal Health) and conducted at St Mary’s Hospital (part of Imperial College Healthcare NHS Trust) is expected to demonstrate the high quality physiological data that can be continuously acquired by wireless, unobtrusive Sensium-enabled devices. Initial results are expected by the end of December this year.

In the milestone trial, volunteers and patient groups will be provided with a wearable Sensium digital “plaster” or “patch” that can continuously monitor multiple vital signs, including temperature, heart rate and respiration. The focus of the trial will be to verify that the physiological data acquired by the digital plaster system within a clinical setting is equivalent to that acquired using current gold-standard monitors in use in hospitals – equipment that is often bulky, expensive and fixed, such that patient mobility is impaired. The Sensium digital plaster is wireless and unobtrusive, meaning that patients can remain ambulatory in hospital while still being monitored. This flexibility allows continuous vital sign monitoring to be extended to patients who would not normally be monitored, thereby offering the potential to increase patient safety. The Sensium digital plaster is a disposable device with a working lifetime of several days, after which the plaster is disposed of in the appropriate waste receptacle.

The trial is being conducted in three phases, an initial phase with non-patient volunteers followed by two patient study groups: patients recovering from surgery, and patients with specific medical conditions in the general wards.

The digital plaster is based on Toumaz’s new generation AMx™ semiconductor IP platform, which enables Sensium wireless technology that has been specifically designed for Medical Body Area Networks (MBANs) and non-intrusive physiological monitoring. Sensium provides the complete wireless infrastructure to allow healthcare providers to monitor the human body continuously, wirelessly and intelligently and at low-cost, with the robustness and medical compliance normally associated with considerably more expensive capital equipment. Sensium technology has already been validated and CE marked in Toumaz’s Life Pebble non-disposable body worn monitoring devices.
The Sensium digital plaster is targeted for use in clinical monitoring applications such as acute care, general ward environments, tele-care, chronic disease monitoring, and in care home settings. For all these applications, disposability provides convenience, simplicity and patient comfort while ensuring infection control is maintained to the highest standards. Powered by thin batteries, body-worn Sensium-enabled monitors deliver clinical-quality data and intelligently integrate it into an electronic medical record via a network built on Toumaz’s power-optimised wireless operating and networking system, Nano Sensor Protocol (NSP).

Dr Stephen Brett, a Consultant in Intensive Care Medicine at Imperial College Healthcare NHS Trust and an Honorary Senior Lecturer at Imperial College London, who is leading the trial, explains: “This technology has the potential to improve the capturing of patient’s vital signs within all areas of the hospital – enabling key physiological data to be acquired at an increased frequency, with the minimum of inconvenience to patients, and without the requirement to connect patients to immobile pieces of equipment. This raises the possibility of technology: improving hospital safety systems; enhancing the efficiency of adding vital sign data to patient records: and potentially freeing valuable nursing staff time for other patient care responsibilities.”
“This is a very significant step on the path towards pervasive deployment of Sensium-enabled monitoring devices across a range of healthcare settings,” comments Toumaz Technology Co-Founder Keith Errey. “Current patient data acquisition systems are mostly hospital-based, expensive, generally wired, and non-mobile. Even so-called portable equipment is still large, and prohibitively expensive for widespread use. Our Sensium technology platform is the step change that enables the development of clinical grade yet low-cost and unobtrusive wireless body monitoring solutions for the first time. We are tremendously excited with the success so far of this important trial in partnership with Imperial College London.”

Professor Chris Toumazou FRS, CEO and Founder of Toumaz Holdings, and Director of the Institute of Biomedical Engineering at Imperial College London, adds: “It is fantastic to see the Sensium technology coming to commercial fruition, and for us to be launching this study at Imperial College Healthcare NHS Trust. This is a key stage in our commercial journey and one that opens the door to some very exciting applications of our technology in clinical environments next year.” He continues: “The business case is simple: by using the disposable digital plaster to monitor on a 24-7 basis, critical medical information can be monitored that would not otherwise have been detected. This preventative form of medicine will mean that less people could require intensive care in the future, saving lives and at the same time providing greater efficiencies and cost savings to the NHS. Once proven in a hospital setting then the digital plaster can be deployed in the home in the same way.”
Members of the media interested in scheduling a briefing with Toumaz can do so by contacting Nicky Denovan.

The new trial forms part of the Academic Health Science Centre (AHSC), a unique kind of partnership between Imperial College London and Imperial College Healthcare NHS Trust, formed in October 2007. The AHSC’s aim is to improve the quality of life of patients and populations by taking new discoveries and translating them into new therapies as quickly as possible.

About Sensium™
Toumaz Technology’s Sensium™ technology platform enables the non-intrusive acquisition of real-time, continuous physiological data for a wide range of health and lifestyle management applications, including remote healthcare, wellness and wireless monitoring at the bedside.
Sensium provides an open platform to develop revolutionary wireless devices that can continuously monitor multiple vital signs in real-time, and feed back high-quality information to health professionals via PCs, PDAs and smart phones.

About Toumaz Technology
Toumaz Technology Limited (toumaz.com) is the leading provider of ultra-low power wireless infrastructure for body monitoring solutions.
Toumaz’s ultra low-power smart sensor interface and transceiver platform – Sensium™ – enables non-intrusive, real-time wireless monitoring of multiple vital signs for a wide range of healthcare and lifestyle management applications. Based on Toumaz’s patented ultra-low power Advanced Mixed Signal (AMx)™ technology, the Sensium provides the enabling technology to connect the mobile individual to healthcare providers – simply, affordably and unobtrusively.

For healthcare professionals, this transforms the possibilities for pro-active monitoring and improved quality of care. For patients, it delivers new opportunities for lifestyle-compatible, personalised healthcare, as well as better therapeutic outcomes.

Submitted by NeonDrum on behalf of Toumaz Technology
Nicky Denovan, T: +44 7747 017654

 
 
Your Banner Ad Here instead - Showing along with ALL Articles covering Medical Services / Equipment Announcements

Replace these Affiliate Programs at ANYTIME! Your banner here within the next hour. Learn How!


 

Written by / Agency / Source: NeonDrum Ltd

 
 

Availability: All Regions (Including Int'l)

 

Traffic Booster: [/] Quick NewswireToday Visibility Checker

 

Distribution / Indexing: [+]

 
 
# # #
 
 
  Your Banner Ad showing on ALL
Medical Services / Equipment articles,
CATCH Visitors via Your Competitors Announcements!


Toumaz in Clinical Trial of Sensium-Enabled™ Digital Plaster

Company website links NOT available to basic submissions
It is OK to republish and/or LINK any newswire for any legitimate media purpose as long as you name NewswireToday and LINK as the source.
 
Publisher Contact: Liz Hartney 
+44(0)75 1051 8732 news[.]neondrum.com
 
Newswire Today - PRZOOM / PRTODAY disclaims any content contained in this article. If you need/wish to contact the company who published the current release, you will need to contact them - NOT us. Issuers of articles are solely responsible for the accuracy of their content. Our complete disclaimer appears here.
IMPORTANT INFORMATION: Issuance, publication or distribution of this press release in certain jurisdictions could be subject to restrictions. The recipient of this press release is responsible for using this press release and the information herein in accordance with the applicable rules and regulations in the particular jurisdiction. This press release does not constitute an offer or an offering to acquire or subscribe for any NeonDrum Ltd securities in any jurisdiction including any other companies listed or named in this release.

Medical Services / Equipment via RSSAdd NewswireToday - PRZOOM Headline News to FeedBurner
Find who RetweetFollow @NewswireTODAY

Are you the owner of this article?, Turn it PREMIUM with your LOGO instead - and make it 3rd party Ads-Free! within the next hour!


Read Latest Articles From NeonDrum Ltd / Company Profile


Read Medical Services / Equipment Most Recent Related Newswires:

Bruker Launches IconIR Nanoscale IR Spectroscopy Platform
Artificial Intelligence to Boost the Global Wound Care Market by 2026 with Minimal Intervention Solutions Finds Frost & Sullivan
Imec Signs Licensing Agreement with miDiagnostics to Commercialize its Patented Technology for Fast and Reliable COVID-19 Diagnosis
Withings Announces the FDA Clearance of ScanWatch its Most Medically Advanced Hybrid Smartwatch
Bruker Launches the Q4 POLO - Compact Spark-OES Metals Analyzer
Respiratory Health Management Market to Expedite Digital, Smart, and Portable Solutions Says Frost & Sullivan
Bruker Joins PANACEA Network to Broaden Access to NMR for European Chemistry Community
High-end Global Computed Tomography Purchases to Propel the High-end CT Segment Revenue Finds Frost & Sullivan
KRAIBURG TPE Introduces Ergonomically Designed Healthcare Equipment
Fujifilm Lauded by Frost & Sullivan for Disrupting the Operating Room Space with its Systems Integration Solution
BASF’s Irgastab® Enables LOTTE Chemical to Deliver High-clarity Medical Polypropylene for Syringes Used in COVID-19 Vaccinations
Withings and One Drop Partner to Bring Best-in-class Medical Devices to Multi-condition Employer Program
BIOTRONIK Applauded by Frost & Sullivan for its Disruptive Implantable Cardiac Monitoring Device, BIOMONITOR IIIm
Sensor Technologies for Pressure Injury Prevention Improve Outcomes and Operational Efficiency for Hospitals Finds Frost & Sullivan
New Bruker NMR Life Science Research Solutions Enable Functional Structural and Cellular Biology Research

Boost Your Social Network
& Crowdfunding Campaigns


LIFETIME SOCIAL MEDIA WALL
NewswireToday Celebrates 10 Years in Business


PREMIUM Members


Visit  Limelon Advertising, Co.

Visit  JobsWare.com





 
  ©2021 NewswireToday — Limelon Advertising, Co.
Home | About | Advertise/Pricing | Contact | Investors | Privacy/TOS | Sitemap | FRANCAIS
newswire, PR press releases distribution service magazines engine news alert newsroom press room breaking news public relations articles company news alerts newswiredistribution ezine bizentrepreneur biznewstoday digital business report market search pr firms agencies reports distri-bution today investor relation successful internet entrepreneurs newswire distribution prtoday.com newswiredistribution asianewstoday bizwiretoday USA pr UK today - NOT affiliated with PRNewswire as we declined their partnership offer in 2013
 
PRTODAY & NewswireTODAY are proudly NOT affiliated with USA TODAY (usatoday.com)